Efficient inhibition of human colorectal carcinoma growth by RNA interference targeting polo-like kinase 1 in vitro and in vivo

Cancer Biotherapy and Radiopharmaceuticals

Volumn 26, Issue 4, 2011, Pages 427-436

  Xu, Wen Jing ^a,b   Zhang, Shuang ^a   Yang, Yang ^a   Zhang, Na ^a   Wang, Wei ^a   Liu, Sheng Yong ^a   Tian, Hong Wei ^a   Dai, Lei ^a   Xie, Qian ^a   Zhao, Xia ^c   Wei, Yu Quan ^a   Deng, Hong Xin ^a  

^a SICHUAN UNIVERSITY   (China)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

^c SICHUAN UNIVERSITY   (China)

Author keywords

apoptosis; colorectal carcinoma; polo like kinase 1 (PLK1); RNA interference (RNAi)

Indexed keywords

CD31 ANTIGEN; MESSENGER RNA; POLO LIKE KINASE 1; SHORT HAIRPIN RNA;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; COLORECTAL CARCINOMA; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NICK END LABELING; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; CELL CYCLE PROTEINS; COLORECTAL NEOPLASMS; DOWN-REGULATION; FEMALE; GENE THERAPY; HCT116 CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80051745832     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2010.0922     Document Type: Article

References (48)

1. Fenton B, Glover DM. A conserved mitotic kinase active at late anaphase-telophase in syncytial Drosophila embryos. Nature 1993;363:637.
2. Hamanaka R, Maloid S, Smith MR, et al. Cloning and characterization of human and murine homologues of the Drosophila polo serine-threonine kinase. Cell Growth Differ 1994;5:249.
3. Strebhardt K, Ullrich A. Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer 2006;6:321.
4. Hamanaka R, Smith MR, OConnor PM, et al. Polo-like kinase is a cell cycle-regulated kinase activated during mitosis. J Biol Chem 1995;270:21086.
5. Smits VA, Medema RH. Checking out the G2/M transition. Biochim Biophys Acta 2001;1519:1.
6. Glover DM, Hagan IM, Tavares AA. Polo-like kinases: A team that plays throughout mitosis. Genes Dev 1998;12:3777.
7. Lu LY, Wood JL, Minter-Dykhouse K, et al. Polo-like kinase 1 is essential for early embryonic development and tumor suppression. Mol Cell Biol 2008;28:6870.
8. Ando K, Ozaki T, Yamamoto H, et al. Polo-like kinase 1 (Plk1) inhibits p53 function by physical interaction and phosphorylation. J Biol Chem 2004;279:25549.
9. Komatsu S, Takenobu H, Ozaki T, et al. Plk1 regulates liver tumor cell death by phosphorylation of TAp63. Oncogene 2009;28:3631.
10. Koida N, Ozaki T, Yamamoto H, et al. Inhibitory Role of Plk1 in the regulation of p73-dependent apoptosis through physical interaction and phosphorylation. J Biol Chem 2008; 283:8555.
11. Winkles JA, Alberts GF. Differential regulation of polo-like kinase 1, 2, 3, and 4 gene expression in mammalian cells and tissues. Oncogene 2005;24:260.
12. Lobjois V, Jullien D, Bouché JP, et al. The polo-like kinase 1 regulates CDC25B-dependent mitosis entry. Biochim Biophys Acta 2009;1793:462.
13. Mundt KE, Golsteyn RM, Lane HA, et al. On the regulation and function of human polo-like kinase 1 (PLK1): Effects of overexpression on cell cycle progression. Biochem Biophys Res Commun 1997;239:377.
14. Weichert W, Kristiansen G, Winzer KJ, et al. Polo-like kinase isoforms in breast cancer: Expression patterns and prognostic implications. Virchows Arch 2005;446:442.
15. Takahashi T, Sano B, Nagata T, et al. Polo-like kinase 1 (PLK1) is overexpressed in primary colorectal cancers. Cancer Sci 2003;94:148.
16. Gao Q, Huang X, Tang D, et al. Influence of chk1 and plk1 silencing on radiation- or cisplatin-induced cytotoxicity in human malignant cells. Apoptosis 2006;11:1789.
17. Zhao C, Gong L, Li W, et al. Overexpression of Plk1 promotes malignant progress in human esophageal squamous cell carcinoma. J Cancer Res Clin Oncol 2009;136:9.
18. Dietzmann K, Kirches E, von Bossanyi, et al. Increased human polo-like kinase-1 expression in gliomas. J Neurooncol 2001;53:1.
19. Schmit TL, Zhong W, Setaluri V, et al. Targeted depletion of polo-like kinase (Plk) 1 through lentiviral shRNA or a smallmolecule inhibitor causes mitotic catastrophe and induction of apoptosis in human melanoma cells. J Invest Dermatol 2009;129:2843.
20. Schmit TL, Zhong W, Nihal M, et al. Polo-like kinase 1 (Plk1) in non-melanoma skin cancers. Cell Cycle 2009;8:2697.
21. Wolf G, Elez R, Doermer A, et al. Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer. Oncogene 1997;14:543.
22. Weichert W, Denkert C, Schmidt M, et al. Polo-like kinase isoform expression is a prognostic factor in ovarian carcinoma. Br J Cancer 2004;90:815.
23. Weichert W, Schmidt M, Jacob J, et al. Overexpression of polo-like kinase 1 is a common and early event in pancreatic cancer. Pancreatology 2005;5:259.
24. Weichert W, Schmidt M, Gekeler V, et al. Polo-like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades. Prostate 2004;60:240.
25. Kneisel L, Strebhardt K, Bernd A, et al. Expression of pololike kinase (PLK1) in thin melanomas: A novel marker of metastatic disease. J Cutan Pathol 2002;29:354.
26. Rizki A, Mott JD, Bissell MJ. Polo-like kinase 1 is involved in invasion through extracellularmatrix.CancerRes 2007;67:11106.
27. Takaki T, Trenz K, Costanzo V, et al. Polo-like kinase 1 reaches beyond mitosis-Cytokinesis, DNA damage response, and development. Curr Opin Cell Biol 2008;20:650.
28. Petronczki M, Lénárt P, Peters JM, et al. Polo on the rise-from mitotic entry to cytokinesis with Plk1. Dev Cell 2007;14:646.
29. Ma YP, Yang Y, Zhang S, et al. Efficient inhibition of lung cancer in murine model by plasmid-encoding VEGF short hairpin RNA in combination with low-dose DDP. J Exp Clin Cancer Res 2010;29:56.
30. Robbins M, Judge A, Ambegia E, et al. Misinterpreting the therapeutic effects of small interfering RNA caused by immune stimulation. Hum Gene Ther 2008;19:991.
31. Judge A, MacLachlan I. Overcoming the innate immune response to small interfering RNA. Hum Gene Ther 2008;19:111.
32. Parkin DM, Bray F, Ferlay J, et al. Global Cancer Statistics, CA Cancer J Clin 2005;55:74.
33. Santarius T, Shipley J, Brewer D, et al. A census of amplified and overexpressed human cancer genes. Nat Rev Cancer 2010;10:59.
34. Pérez de Castro I, de Cárcer G, Malumbres M. A census of mitotic cancer genes: New insights into tumor cell biology and cancer therapy. Carcinogenesis 2007;28:889.
35. Li R, Sonik A, Stindl R, et al. Aneuploidy vs. gene mutation hypothesis of cancer: Recent study claims mutation but is found to support aneuploidy. Proc Natl Acad Sci U S A 2000;97:3236.
36. Murga M, Fernández-Capetillo O. Genomic instability: On the birth and death of cancer. Clin Transl Oncol 2007; 9:216.
37. Spänkuch B, Heim S, Kurunci-Csacsko E, et al. Downregulation of Polo-like kinase 1 elevates drug sensitivity of breast cancer cells in vitro and in vivo. Cancer Res 2006;66: 5836.
38. Takai N, Hamanaka R, Yoshimatsu J, et al. Polo-like kinases (Plks) and cancer. Oncogene 2005;24:287.
39. Kaiser S, Park YK, Franklin JL, et al. Transcriptional recapitulation and subversion of embryonic colon development by mouse colon tumor models and human colon cancer. Genome Biol 2007;8:R131.
40. Rödel F, Keppner S, Capalbo G, et al. Polo-like kinase 1 as predictive marker and therapeutic target for radiotherapy in rectal cancer. Am J Pathol 2010;177:918.
41. Fan Y, Zheng S, Xu ZF, et al. Apoptosis induction with pololike kinase-1 antisense phosphorothioate oligodeoxynucleotide of colon cancer cell line SW480. World J Gastroenterol 2005;11:4596.
42. Schöffski P. Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology. Oncologist 2009:14:559.
43. Lee YS, Nakahara K, Pham JW, et al. Distinct roles for Drosophila dicer-1 and dicer-2 in the siRNA/miRNA silencing pathways. Cell 2004;117:69.
44. Haasnoot J, Westerhout EM, Berkhout B. RNA interference against viruses: Strike and counterstrike. Nat Biotechnol 2007; 25:1435.
45. Manjunath N, Dykxhoorn DM. Advances in synthetic siRNA delivery. Discov Med 2010;9:418.
46. Nguyen LT, Atobe K, Barichello JM, et al. Complex formation with plasmid DNA increases the cytotoxicity of cationic liposomes. Biol Pharm Bull 2007;30:8.
47. Fedorov Y, Anderson EM, Birmingham A, et al. Off-target effects by siRNA can induce toxic phenotype. RNA 2006; 12:1188.
48. Robbins M, Judge A, MacLachlan I. siRNA and innate immunity. Oligonucleotides 2009;19:89.